Investigating how RNF168 affects cancers with BRCA1 mutations
Examining the Role of RNF168 Activity in BRCA1 Mutant Cancers
['FUNDING_OTHER'] · WASHINGTON UNIVERSITY · NIH-10910988
This study is looking into how certain changes in the BRCA1 gene affect cancer treatment, especially with drugs called PARP inhibitors, to help understand why some patients respond well to these treatments while others don’t, which could lead to better options for people with BRCA1 mutations.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10910988 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the mechanisms of DNA damage signaling in cancers caused by mutations in the BRCA1 gene. It aims to explore how these mutations affect the response to treatments like PARP inhibitors, which are designed to exploit the weaknesses in cancer cells' DNA repair processes. By studying the role of RNF168 in these cancers, the research seeks to identify why some tumors respond to treatment while others develop resistance. Patients with BRCA1 mutations may benefit from insights gained about their cancer's behavior and treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with BRCA1 mutant cancers, particularly those who have undergone treatment with PARP inhibitors.
Not a fit: Patients without BRCA1 mutations or those with cancers unrelated to BRCA1 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with BRCA1 mutant cancers, potentially enhancing the effectiveness of existing therapies.
How similar studies have performed: Previous research has shown promising results in understanding DNA damage response mechanisms in BRCA1 mutant cancers, suggesting that this approach has potential for significant advancements.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KRAIS, JOHN — WASHINGTON UNIVERSITY
- Study coordinator: KRAIS, JOHN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.